Product details
Catalog number 45280-AAT
Price for 45280-AAT
Size / count 100 Tests
Power Styramide™ Signal Amplification (PSA™ ) system is one of the most sensitive methods that can detect extremely low-abundance targets in cells and tissues with improved fluorescence signal 10-50 times higher than the widely used tyramide (TSA) reagents.
The catalog number for IFluor® 594 PSA™ Imaging Kit with Goat Anti-Mouse IgG is 45280-AAT.
IFluor® 594 PSA™ Imaging Kit with Goat Anti-Mouse IgG is available in the following size(s): 100 Tests.
IFluor® 594 PSA™ Imaging Kit with Goat Anti-Mouse IgG is currently made to order / not held in immediate stock. Contact us for lead time.
IFluor® 594 PSA™ Imaging Kit with Goat Anti-Mouse IgG is manufactured by AAT Bioquest.
Estimated delivery time for IFluor® 594 PSA™ Imaging Kit with Goat Anti-Mouse IgG is approximately 15 business day(s), depending on your location.
The safety data sheet for IFluor® 594 PSA™ Imaging Kit with Goat Anti-Mouse IgG is available here: https://cdn.gentaur.com/products/271/7362530/msds/45280-aat.pdf.
Power Styramide™ Signal Amplification (PSA™ ) system is one of the most sensitive methods that can detect extremely low-abundance targets in cells and tissues with improved fluorescence signal 10-50 times higher than the widely used tyramide (TSA) reagents.
Shelf life and expiration dates vary by product and are shown on the product listing and label. Products used beyond their expiration date are not eligible for performance-related returns or refunds, so please check the lot number and expiry before use.
The expression system, such as E. coli, HEK293, or insect cells, is listed on the datasheet under production details, which can affect post-translational modifications relevant to your application.
As a consumer, you have a 14-day right of withdrawal from receipt under EU consumer protection law, submitted via our withdrawal/cancellation request form. Note this applies to unused, undamaged products, and doesn’t override the expiry/storage conditions on performance-based claims.